Breckenridge Announces Approval for Lansoprazole Delayed-Release Rx Capsules
BOCA RATON, Fla., Dec. 18, 2012 /PRNewswire/ — Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Prescription Lansoprazole Delayed-Release Capsules. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Natco Pharma Limited, and will be available in both 15mg and 30mg strengths. Lansoprazole Delayed-Release Rx Capsules are AB rated to Prevacid®, a Proton Pump Inhibitor (PPI) drug marketed by Takeda Pharmaceuticals, USA.
Breckenridge is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, and Liquids, and Powders.
SOURCE Breckenridge Pharmaceutical, Inc.